Literature DB >> 12659682

Androgen-independent prostate cancer: potential role of androgen and ErbB receptor signal transduction crosstalk.

Soha Salama El Sheikh1, Jan Domin, Paul Abel, Gordon Stamp, El-Nasir Lalani.   

Abstract

In prostate cancer (PC), increasing evidence suggests that androgen receptor (AR) signalling is functional under conditions of maximal androgen blockade. PC cells survive and proliferate in the altered hormonal environment possibly by interactions between growth factor-activated pathways and AR signalling. The present review article summarizes the current evidence of this crosstalk and focuses on the interactions among the ErbB receptor network, its downstream pathways, and the AR. The potential role of this crosstalk in the development of androgen independence and in relation to antiandrogen therapy is discussed. Such interactions provide insight into possible complementary or additional strategies in the management of PC.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12659682      PMCID: PMC1502396          DOI: 10.1016/s1476-5586(03)80001-5

Source DB:  PubMed          Journal:  Neoplasia        ISSN: 1476-5586            Impact factor:   5.715


  122 in total

1.  Rapid signalling by androgen receptor in prostate cancer cells.

Authors:  H Peterziel; S Mink; A Schonert; M Becker; H Klocker; A C Cato
Journal:  Oncogene       Date:  1999-11-04       Impact factor: 9.867

Review 2.  Signaling by distinct classes of phosphoinositide 3-kinases.

Authors:  B Vanhaesebroeck; M D Waterfield
Journal:  Exp Cell Res       Date:  1999-11-25       Impact factor: 3.905

Review 3.  Cellular survival: a play in three Akts.

Authors:  S R Datta; A Brunet; M E Greenberg
Journal:  Genes Dev       Date:  1999-11-15       Impact factor: 11.361

Review 4.  Small bioactive peptides and cell surface peptidases in androgen-independent prostate cancer.

Authors:  J B Nelson; M A Carducci
Journal:  Cancer Invest       Date:  2000       Impact factor: 2.176

5.  Increased AKT activity contributes to prostate cancer progression by dramatically accelerating prostate tumor growth and diminishing p27Kip1 expression.

Authors:  J R Graff; B W Konicek; A M McNulty; Z Wang; K Houck; S Allen; J D Paul; A Hbaiu; R G Goode; G E Sandusky; R L Vessella; B L Neubauer
Journal:  J Biol Chem       Date:  2000-08-11       Impact factor: 5.157

Review 6.  EGF receptor signaling in prostate morphogenesis and tumorigenesis.

Authors:  H G Kim; J Kassis; J C Souto; T Turner; A Wells
Journal:  Histol Histopathol       Date:  1999-10       Impact factor: 2.303

7.  Cancer statistics, 2000.

Authors:  R T Greenlee; T Murray; S Bolden; P A Wingo
Journal:  CA Cancer J Clin       Date:  2000 Jan-Feb       Impact factor: 508.702

8.  Trends in prostate cancer incidence, mortality and survival in England and Wales 1971-1998.

Authors:  A Majeed; P Babb; J Jones; M Quinn
Journal:  BJU Int       Date:  2000-06       Impact factor: 5.588

9.  Steroid-induced androgen receptor-oestradiol receptor beta-Src complex triggers prostate cancer cell proliferation.

Authors:  A Migliaccio; G Castoria; M Di Domenico; A de Falco; A Bilancio; M Lombardi; M V Barone; D Ametrano; M S Zannini; C Abbondanza; F Auricchio
Journal:  EMBO J       Date:  2000-10-16       Impact factor: 11.598

10.  Evidence for clonal outgrowth of androgen-independent prostate cancer cells from androgen-dependent tumors through a two-step process.

Authors:  N Craft; C Chhor; C Tran; A Belldegrun; J DeKernion; O N Witte; J Said; R E Reiter; C L Sawyers
Journal:  Cancer Res       Date:  1999-10-01       Impact factor: 12.701

View more
  11 in total

Review 1.  A review of the past, present, and future directions of neoplasia.

Authors:  Alnawaz Rehemtulla; Brian D Ross
Journal:  Neoplasia       Date:  2005-12       Impact factor: 5.715

2.  Network-based prediction for sources of transcriptional dysregulation using latent pathway identification analysis.

Authors:  Lisa Pham; Lisa Christadore; Scott Schaus; Eric D Kolaczyk
Journal:  Proc Natl Acad Sci U S A       Date:  2011-07-25       Impact factor: 11.205

Review 3.  Peptide-Based Therapeutics for Oncology.

Authors:  Elizaveta Fisher; Kirill Pavlenko; Alexander Vlasov; Galina Ramenskaya
Journal:  Pharmaceut Med       Date:  2019-02

Review 4.  Epidermal growth factor receptor expression escapes androgen regulation in prostate cancer: a potential molecular switch for tumour growth.

Authors:  A M Traish; A Morgentaler
Journal:  Br J Cancer       Date:  2009-11-03       Impact factor: 7.640

5.  A functionally significant cross-talk between androgen receptor and ErbB2 pathways in estrogen receptor negative breast cancer.

Authors:  Ali Naderi; Luke Hughes-Davies
Journal:  Neoplasia       Date:  2008-06       Impact factor: 5.715

6.  Predictive value of PTEN and AR coexpression of sustained responsiveness to hormonal therapy in prostate cancer--a pilot study.

Authors:  Soha Salama El Sheikh; Hanna M Romanska; Paul Abel; Jan Domin; El-Nasir Lalani
Journal:  Neoplasia       Date:  2008-09       Impact factor: 5.715

7.  Specificity and heregulin regulation of Ebp1 (ErbB3 binding protein 1) mediated repression of androgen receptor signalling.

Authors:  Y Zhang; A W Hamburger
Journal:  Br J Cancer       Date:  2005-01-17       Impact factor: 7.640

8.  Data analysis algorithm for the development of extracellular miRNA-based diagnostic systems for prostate cancer.

Authors:  O E Bryzgunova; I A Zaporozhchenko; E A Lekchnov; E V Amelina; M Yu Konoshenko; S V Yarmoschuk; O A Pashkovskaya; A A Zheravin; S V Pak; E Yu Rykova; P P Laktionov
Journal:  PLoS One       Date:  2019-04-10       Impact factor: 3.240

9.  pathfindR: An R Package for Comprehensive Identification of Enriched Pathways in Omics Data Through Active Subnetworks.

Authors:  Ege Ulgen; Ozan Ozisik; Osman Ugur Sezerman
Journal:  Front Genet       Date:  2019-09-25       Impact factor: 4.599

10.  Gene Expression Signature Predictive of Neuroendocrine Transformation in Prostate Adenocarcinoma.

Authors:  Paola Ostano; Maurizia Mello-Grand; Debora Sesia; Ilaria Gregnanin; Caterina Peraldo-Neia; Francesca Guana; Elena Jachetti; Antonella Farsetti; Giovanna Chiorino
Journal:  Int J Mol Sci       Date:  2020-02-06       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.